Table 7. Recommendation of adjuvant therapy for TNBC cancer without neoadjuvant therapy.

Stratification	Level I recommendations	Level II recommendations	Level III recommendations
Primary treatment
In the presence of any of the following conditions: positive lymph nodes, tumor sized >2 cm	(I) AC→T (1A)	(I) TAC (1B)	(I) AC→TP (2B)
	(II) ddAC-ddT (1A)	(II) TP (2A)	(II) FEC→T (2B)
Patients at low risk of recurrence: tumor sized ≤2 cm and with negative lymph nodes	(I) TC ×4 (1A)	(I) AC→T (2A)
	(II) AC (1A)	(II) TC ×6 (2A)
Extended therapy
In the presence of any of the following conditions: (I) positive lymph nodes; (II) tumor sized >2 cm		Chemotherapy followed by capecitabine (2A) (BRCA wild-type)
		Chemotherapy followed by olaparib (1B) (with BRCA mutation type)
Negative lymph nodes and tumor sized 1–2 cm		Chemotherapy followed by sequential capecitabine (2B) (BRCA wild-type)

A, anthracyclines, including epirubicin, pirarubicin, and doxorubicin; T, taxanes, including docetaxel and paclitaxel; C, cyclophosphamide; Cb, carboplatin; E, eporubicin; F, fluorouracil; TNBC, triple-negative breast cancer.